(NASDAQ: BCAB) Bioatla's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.94%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Bioatla's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast BCAB's revenue for 2024 to be $721,450,755, with the lowest BCAB revenue forecast at $721,450,755, and the highest BCAB revenue forecast at $721,450,755. On average, 1 Wall Street analysts forecast BCAB's revenue for 2025 to be $275,594,188, with the lowest BCAB revenue forecast at $275,594,188, and the highest BCAB revenue forecast at $275,594,188.
In 2026, BCAB is forecast to generate $1,123,058,342 in revenue, with the lowest revenue forecast at $1,123,058,342 and the highest revenue forecast at $1,123,058,342.